To test our hypothesis that the TRIB2 protein confers resistance to anti-cancer drugs, we first generated and then examined the sensitivity of several stable, isogenic TRIB2 in vitro models (Supplementary Table 1; Supplementary Fig. 1) after treatment with the dual PI3K/mTOR kinase inhibitor BEZ235. Here, MTOR is linked to cancer.